Familial Amyloid Cardiomyopathy Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Jul 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated with familial amyloid cardiomyopathy, which includes V1221, P24S, V20I, A45T, Gly47Val, Glu51Gly, Gln92Lys, I68L, and L111M. Most common mutation is V1221, which is substitution of isoleucine for valine at position 122 that occurs in high frequency in African-Americans, which favors the growth of familial amyloid cardiomyopathy treatment market.

European Medicines Agency have approved drug named tafamids (Vyndaqel) for slow progression of familial amyloid cardiomyopathy in year 2013 which is expected to favor the market of familial amyloid cardiomyopathy treatment. Most of the pharmaceuticals companies are developing drugs for familial amyloid cardiomyopathy treatment, as it is associated with progressive heart failure and it is universally fatal. Symptoms for familial amyloid cardiomyopathy are weight loss, nausea, fatigue, dizziness and collapse, palpitations, abnormal heart rhythms, disrupted sleep, and angina. Genetic tests are recommended for detection of TTR gene.

Familial Amyloid Cardiomyopathy Treatment Market Taxonomy

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

By Geographic Type

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Rise in amount of transthyretin protein in the body fuels the familial amyloid cardiomyopathy treatment market

Transthyretin protein is formed in the body abundantly due to inherited transthyretin gene alteration, which leads to familial amyloid cardiomyopathy as gene associated transcribes the protein. Gene alteration in body leads to alteration in sequence of body proteins. Familial amyloid cardiomyopathy are inherited by autosomal dominant allele, which can inherit the familial amyloid cardiomyopathy condition to offsprings from one of the parent. Only one copy of mutated gene is sufficient to cause the disease, which is expected to show growth in the familial amyloid cardiomyopathy market. Familial amyloid cardiomyopathy is critical disease leading to heart failure, which can favor the market. According to Amyloidosis Foundation (AF), which provides early diagnosis and advanced treatment, familial amyloid cardiomyopathy are rarely found with statistics estimating 1 per 100,000 population suffering from familial amyloid cardiomyopathy disease.

Regional growth engines of the familial amyloid cardiomyopathy treatment

On the basis of regional segmentation, the familial amyloid cardiomyopathy market can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to BioMed Central journal’s published data in year March 2017, Europeans had highest number of TTR mutations, followed by East Asians, American, Central-South Asians, and Africans which favors the growth of familial amyloid cardiomyopathy market.

The key players dominating the familial amyloid cardiomyopathy market

Familial amyloid cardiomyopathy not only affect lives of people but also affect upcoming generations, due to which manufactures are in process of releasing the drugs, as there are very few drugs approved for familial amyloid cardiomyopathy treatment. Recently in June 2017 the U.S. Food and Drug Administration (FDA), which provides accurate, science-based health information to the public, granted fast track designation to tafamidis the company’s investigational treatment for familial amyloid cardiomyopathy as there were no approved treatment in the U.S. tafamidis with trade name VYNDAQEL® was first approved in Europe. The key players operating the market are Pfizer Inc., SOM Innovation Biotech, S.L., Valeant Pharmaceuticals International, Inc., Ionis Pharmaceuticals, Inc., and AstraZeneca plc.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.